Comirnaty Original/Omicron BA.4-5

bivalent mRNA vaccine targeting original SARS-CoV-2 and Omicron BA.4-5 · BioNTech-Pfizer

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Comirnaty Original/Omicron BA.4-5, covering 2023-06-29 to 2026-01-23. Get the full timeline:

Most recent: Clinical Trial Update: Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine. [NA]

See pricing